QuEra, Quantum Intelligence Team on Quantum Drug Discovery

A new partnership aims to accelerate and enhance how novel drugs are discovered and developed using quantum computing to enhance an AI drug discovery platform.

QuEra Computing and South Korean AI-driven drug development company Quantum Intelligence Corp. (QIC) are collaborating to use QuEra’s neutral atom-type quantum computers with QIC’s QUEST system.

QUEST uses AI algorithms to analyze how electronic charges are distributed in molecules to predict how a drug will behave in the body, which indicates whether it will be safe and effective for patient use.

The partnership aims to use QuEra’s quantum computing to enhance these predictions, thus significantly accelerating drug development.

“At Quantum Intelligence, we are at the forefront of merging quantum and AI technologies to innovate within the biopharmaceutical industry,” said QIC CEO Dr. Hwanho Choi.

“Our work with QuEra Computing will allow us to accurately detect potential side effects at the early stages of drug development, greatly reducing risks and improving the safety and effectiveness of new treatments.”

According to QuEra, its neutral-atom architecture operates at room temperature and is well suited for integration with classical computing infrastructure, including supporting AI systems.

Related:Quantum Computing Market Set to Grow 25x in 10 Years

“This partnership marks an important step in applying quantum computing to drug discovery,” said QuEra chief commercial officer Yuval Boger.

“By combining our strengths in quantum technology with QIC's advanced drug development platform, we hope to achieve significant improvements in how quickly and accurately new medicines are developed and brought to market.”